Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idronoxil - Kazia Therapeutics/Noxopharm

Next Previous
X
Search
Drug Profile

Idronoxil - Kazia Therapeutics/Noxopharm

Alternative Names: NOX-66; Veyonda

Latest Information Update: 28 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Noxopharm
  • Developer Children Cancer Institute; Kazia Therapeutics; Noxopharm
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Hormones; Isoflavones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Cyclin-dependent kinase inhibitors; Sphingosine kinase inhibitors; Src-family kinase modulators; STING1 protein inhibitors; TBK1 protein inhibitors; Tumour-associated NADH oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Prostate cancer
  • Research Influenza virus infections
  • No development reported COVID 2019 infections; Diffuse intrinsic pontine glioma; Nasopharyngeal cancer; SARS-CoV-2 sepsis; Soft tissue sarcoma

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy) in USA (Rectal, Suppository)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Second-line therapy or greater) in Australia (Rectal, Suppository)
  • 28 May 2024 No recent reports of development identified for preclinical development in Nasopharyngeal-cancer in Australia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top